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BACKGROUND
Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations 
in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to sal-
vage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with 
single-agent activity in relapsed or refractory FLT3-mutated AML.
METHODS
In a phase 3 trial, we randomly assigned adults with relapsed or refractory FLT3-
mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per 
day) or salvage chemotherapy. The two primary end points were overall survival 
and the percentage of patients who had complete remission with full or partial 
hematologic recovery. Secondary end points included event-free survival (freedom 
from treatment failure [i.e., relapse or lack of remission] or death) and the percent-
age of patients who had complete remission.
RESULTS
Of 371 eligible patients, 247 were randomly assigned to the gilteritinib group 
and 124 to the salvage chemotherapy group. The median overall survival in the 
gilteritinib group was significantly longer than that in the chemotherapy group 
(9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval 
[CI], 0.49 to 0.83; P<0.001). The median event-free survival was 2.8 months in the 
gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for 
treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The percentage of patients 
who had complete remission with full or partial hematologic recovery was 34.0% 
in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 
18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remis-
sion were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points; 
95% CI, 2.8 to 18.4). In an analysis that was adjusted for therapy duration, adverse 
events of grade 3 or higher and serious adverse events occurred less frequently in 
the gilteritinib group than in the chemotherapy group; the most common adverse 
events of grade 3 or higher in the gilteritinib group were febrile neutropenia 
(45.9%), anemia (40.7%), and thrombocytopenia (22.8%).
CONCLUSIONS
Gilteritinib resulted in significantly longer survival and higher percentages of pa-
tients with remission than salvage chemotherapy among patients with relapsed or 
refractory FLT3-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials 
.gov number, NCT02421939.)
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Patients with acute myeloid leuke-mia (AML) whose disease is refractory to, or relapses after, induction chemotherapy 
have a dismal prognosis with standard chemo-
therapy.1-4 FMS-like tyrosine kinase 3 (FLT3), a 
cytokine receptor tyrosine kinase that is ex-
pressed in early hematopoietic stem and pro-
genitor cells, regulates their proliferation and 
differentiation.5 FLT3-activating mutations occur 
in approximately 30% of patients with AML,6 
primarily as in-frame internal tandem duplica-
tions (ITD) within the juxtamembrane region or 
as missense point mutations in the tyrosine ki-
nase domain (TKD).7-9 In patients with AML, the 
presence of the FLT3 ITD mutation adversely af-
fects survival, both at diagnosis and on failure 
of the initial therapy.10-12
Several FLT3 tyrosine kinase inhibitors, either 
under development or approved for the treat-
ment of AML, vary in kinase selectivity, potency, 
and clinical activity.13-17 Midostaurin, a multitar-
geted inhibitor, is approved in combination with 
standard cytarabine and daunorubicin–based 
chemotherapy for patients with newly diagnosed 
FLT3-mutated AML.18,19 However, for patients with 
relapsed or refractory AML, neither midostaurin 
nor lestaurtinib has conferred durable clinical 
benefit as a single agent.13,14,20 Sorafenib showed 
clinical activity in patients with AML that was 
positive for the FLT3 ITD mutation, but data 
from randomized trials that support its use in 
that context are scarce.16 The FLT3 inhibitor 
quizartinib showed single-agent activity in pa-
tients with relapsed or refractory AML with the 
FLT3 ITD mutation,21 but responses were short-
lived, probably owing to FLT3 TKD mutations 
that emerged during treatment.22 Similar resis-
tance is seen with sorafenib.23 Furthermore, 
quizartinib is myelosuppressive, probably owing 
to its activity against other hematopoietic tyro-
sine kinases, such as c-Kit.24
Gilteritinib is a new, highly selective, oral FLT3 
inhibitor with activity against both FLT3 muta-
tion subtypes (ITD and TKD) and weak activity 
against c-Kit.25,26 Gilteritinib also inhibits the 
tyrosine kinase AXL, which is implicated in FLT3 
inhibitor resistance.26,27 In a phase 1–2 study, 
single-agent gilteritinib therapy resulted in sus-
tained inhibition of FLT3 autophosphorylation 
and, at doses of at least 80 mg per day, led to 
41% of the patients with relapsed or refractory 
FLT3-mutated AML having a composite complete 
remission (complete remission with or without 
normal hematologic recovery); a starting dose of 
120 mg per day was recommended for further 
study.28 To investigate the clinical benefit of 
gilteritinib in the treatment of relapsed or refrac-
tory FLT3-mutated AML, we conducted a multi-
center, randomized trial comparing gilteritinib 
with conventional salvage chemotherapy regimens.
Me thods
Trial Design and Oversight
The randomized, phase 3 ADMIRAL trial was 
conducted at 107 centers in 14 countries and was 
sponsored by Astellas Pharma. The trial was re-
viewed and approved by the institutional review 
board or ethics committee at each participating 
center and was conducted in accordance with 
the principles of the Declaration of Helsinki. All 
the patients provided written informed consent 
at enrollment.
Two authors who were employees of the 
sponsor designed the trial in collaboration with 
four academic authors. Investigators gathered 
and analyzed the data and submitted case-report 
forms to the sponsor, which performed data 
monitoring and statistical analyses. All the authors 
had access to the trial data and were involved in 
data interpretation. The authors and the sponsor 
vouch for the completeness and accuracy of the 
data and for the fidelity of the trial to the proto-
col (available with the full text of this article at 
NEJM.org). The first and last authors wrote the 
manuscript, with additional writing and editorial 
assistance provided by medical writers who were 
funded by the sponsor.
Patients
Patients 18 years of age or older were eligible if 
their disease was refractory to one or two cycles 
of conventional anthracycline-containing induc-
tion therapy or if they had hematologic relapse 
after a complete remission. Patients who were 
not candidates for anthracycline-containing in-
duction regimens could participate if they had 
completed at least one cycle of alternative stan-
dard therapy that had been judged by the inves-
tigators as the appropriate choice to induce re-
mission. At enrollment, patients’ bone marrow 
and blood samples were screened for FLT3 muta-
tions by a central laboratory. Enrollment on the 
basis of local testing for the FLT3 mutation was 
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permitted for patients with rapidly proliferative 
disease. Previous treatment with sorafenib or 
midostaurin as part of first-line induction, con-
solidation, or maintenance therapy was allowed.
FLT3 Mutations
Patients were required to have FLT3 ITD or TKD 
D835 or I836 mutations. The central laboratory 
(Invivoscribe) used a polymerase chain reaction–
based assay that was modeled on published meth-
ods (LeukoStrat CDx).29 FLT3 mutations were 
considered to be present if the mutant-to-non-
mutant allelic ratio was at least 0.05. The median 
FLT3 ITD allelic ratio was established at 0.77, with 
a high FLT3 ITD allelic ratio defined as 0.77 or 
greater and a low ratio as less than 0.77.
Randomization and Treatments
Enrolled patients were randomly assigned in a 
2:1 ratio by an interactive response technology 
system to receive once-daily gilteritinib (120 mg) 
or salvage chemotherapy. Randomization was 
stratified according to response to previous ther-
apy and the chosen chemotherapy, which was 
selected by the local investigator before random-
ization from four possible options: mitoxantrone, 
etoposide, and cytarabine (MEC)20; f ludarabine, 
cytarabine, granulocyte colony-stimulating factor, 
and idarubicin (FLAG-IDA)30; low-dose cytara-
bine; and azacitidine. MEC and FLAG-IDA were 
considered to be high-intensity regimens, and 
low-dose cytarabine and azacitidine were con-
sidered to be low-intensity regimens.
Gilteritinib or chemotherapy was administered 
in 28-day cycles. Patients receiving high-intensity 
chemotherapy were assessed for response on or 
after day 15 to determine the need for a second 
induction cycle; response was measured on day 1 
of cycle 2. Gilteritinib or low-intensity chemo-
therapy was administered until documentation 
of a lack of clinical benefit or the occurrence of 
toxic effects or other discontinuation criterion as 
defined in the protocol. Responses to gilteritinib 
or low-intensity chemotherapy were assessed on 
day 1 of cycles 2 and 3 and every two to three 
cycles thereafter. No crossover between treatment 
groups was permitted. Patients in the gilteritinib 
group who did not have a protocol-defined com-
posite complete remission at the dose of 120 mg 
per day could escalate the dose to 200 mg per 
day; those who had a response and proceeded to 
transplantation continued in the trial and could 
resume gilteritinib therapy 30 to 90 days after 
the transplantation if they had engraftment with-
out relapse and no uncontrolled complications 
of transplantation.
End Points and Assessments
The two primary end points were overall survival 
and the percentage of patients who had complete 
remission with full or partial hematologic recov-
ery. Key secondary end points were event-free 
survival (defined as freedom from treatment fail-
ure [i.e., relapse or lack of remission] or death) 
and the percentage of patients with complete 
remission. Complete remission with full or par-
tial hematologic recovery was evaluated in an 
interim analysis in the gilteritinib group only 
and was summarized in the final analysis for 
both treatment groups. Overall survival, event-
free survival, complete remission, and other end 
points were evaluated in the final analysis. Best 
response was noted at any postbaseline visit.
Treatment response was assessed with the 
use of modified International Working Group 
criteria (Table S1 in the Supplementary Appendix, 
available at NEJM.org).31 Minimal residual dis-
ease was not assessed. Safety was assessed by 
evaluating the incidence of adverse events, includ-
ing evaluation of vital signs, and results from 
clinical laboratory tests, electrocardiograms, and 
ophthalmologic examinations. Patient-reported 
outcomes (from the EuroQoL Group 5-Dimension 
5-Level [EQ-5D-5L] instrument32 and the Func-
tional Assessment of Cancer Therapy–Leukemia33 
questionnaire) are not presented here. Next-
generation sequencing for AML-associated mu-
tations was performed in bone marrow or blood 
DNA samples obtained at baseline (Table S2). 
Expression of AXL (a receptor tyrosine kinase 
associated with drug resistance) was analyzed by 
means of flow cytometry. The postbaseline trans-
fusion status (assessed 29 days after first dose 
until the last treatment dose) was evaluated in 
patients who received gilteritinib treatment for 
at least 84 days; transfusion independence was 
noted if no red-cell or platelet transfusions were 
administered for 56 consecutive days during the 
postbaseline period. (Additional information about 
FLT3 mutations, treatments, dose modifications, 
and assessments is provided in the protocol and 
the Supplementary Appendix.)
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Statistical Analysis
Assuming a 2:1 randomization ratio and that 
10% of the patients would discontinue the trial, 
we calculated that a planned sample of 369 pa-
tients would provide the trial with approximate-
ly 90% power to detect a difference in the esti-
mated median overall survival between the 
gilteritinib group (7.7 months) and the salvage 
chemotherapy group (5.0 months) (hazard ratio 
for death, 0.65) on the basis of 258 deaths at a 
one-sided alpha level of 0.0245. The first planned 
interim analysis — to evaluate the primary end 
point of the percentage of patients who had 
complete remission with full or partial hemato-
logic recovery — occurred when approximately 
141 patients in the gilteritinib group reached the 
time point of at least 112 days (four treatment 
cycles) after the receipt of first dose or after 
randomization; the interim evaluation of com-
plete remission with full or partial hematologic 
recovery rate had no effect on trial conduct. The 
planned final analysis was performed when ap-
proximately 258 deaths had occurred.
Two-sided P values for the analysis of overall 
survival were determined with the use of the 
stratified log-rank test; the Kaplan–Meier method 
and the Greenwood formula were used to deter-
mine overall survival and event-free survival. The 
statistical analysis plan excluded provisions for 
multiplicity correction in the evaluation of sec-
ondary and other outcomes. These results are 
reported as point estimates and 95% confidence 
intervals without adjustment for multiplicity and 
should not be used to infer definitive treatment 
effects. Final efficacy and safety analyses were 
performed in the intention-to-treat population 
(all patients who underwent randomization) and 
the safety population (all patients who had re-
ceived at least one dose of trial treatment), respec-
tively. (Details regarding the statistical analysis 
are provided in the Supplementary Appendix.)
R esult s
Patients
From October 20, 2015, to February 20, 2018, a 
total of 625 patients entered screening. The 
event cutoff of 258 deaths, which triggered the 
final analysis, occurred on September 17, 2018; 
the database was locked on October 19, 2018. A 
total of 371 eligible patients underwent randomi-
zation; 247 were assigned to the gilteritinib group 
and 124 to the chemotherapy group (Fig. 1 and 
Table 1). Overall, 60.6% of the patients had re-
lapsed AML (median duration of first remission, 
6.0 months; range, 0.3 to 60.0), and 39.4% had 
primary refractory disease. Most patients (83.8%) 
had received previous induction therapy with 
anthracyclines but not FLT3 inhibitors (87.6%); 
21 patients (5.7%) had received the FLT3 inhibitor 
midostaurin. Receipt of previous hematopoietic-
cell transplantation did not affect patient assign-
ment to the high-intensity and low-intensity 
chemotherapy regimens. Nearly all the patients 
(94.1%) who received high-intensity chemotherapy 
received one treatment cycle. The median dura-
tion of low-intensity chemotherapy was 4 weeks 
(low-dose cytarabine, 4 weeks [range, 2 to 31]; 
azacitidine, 4 weeks [range, 1 to 26]). The median 
number of cycles of gilteritinib therapy received 
was 5 (range, 1 to 33).
At the time of this analysis, 110 patients 
remained alive and 38 were continuing therapy 
with gilteritinib. Common reasons for the dis-
continuation of gilteritinib were relapse, progres-
sion, or lack of efficacy (50.2%), death (14.6%), 
and adverse events (11.3%). Common reasons for 
the discontinuation of chemotherapy were relapse, 
progression, or lack of efficacy (39.5%), with-
drawal by the patient (8.1%), physician decision 
(8.9%), and death (8.1%).
Efficacy
The median duration of follow-up for overall 
survival was 17.8 months. The median overall 
survival was significantly longer among patients 
in the gilteritinib group than among those in the 
chemotherapy group (9.3 months vs. 5.6 months; 
two-sided P<0.001) (Fig. 2A). The hazard ratio 
for death with gilteritinib as compared with 
chemotherapy was 0.64 (95% confidence interval 
[CI], 0.49 to 0.83). The percentages of patients 
who were alive at 1 year were 37.1% in the gilteri-
tinib group and 16.7% in the chemotherapy 
group. A consistent pattern of longer survival 
with gilteritinib than with chemotherapy was 
noted across multiple subgroups, including the 
high-intensity and low-intensity chemotherapy 
cohorts (Fig. 2B) and the high FLT3 ITD allelic 
ratio subgroup (median overall survival, 7.1 vs. 
4.3 months; hazard ratio for death, 0.49; 95% 
CI, 0.34 to 0.71). Among patients with primary 
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Figure 1. Screening, Randomization, and Treatment.
Of the 625 patients screened, 254 did not undergo randomization: 236 of 625 patients (37.8%) did not continue  
to randomization because inclusion or exclusion criteria were not met or because of absence of a mutation in the 
FMS-like tyrosine kinase 3 gene (FLT3), 10 patients (1.6%) had an adverse event, and 8 (1.3%) withdrew from the 
trial. A total of 25 of 63 patients in the gilteritinib group and all 19 patients in the salvage chemotherapy group who 
underwent hematopoietic stem-cell transplantation subsequently discontinued treatment. The safety population 
comprised all the patients who had received at least one dose of trial treatment. AML denotes acute myeloid leukemia; 
FLAG-IDA fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; and MEC mitoxantrone, 
etoposide, and cytarabine.
371 With relapsed or refractory FLT3-mutated
AML underwent randomization
(intention-to-treat population)
625 Patients with relapsed or refractory AML were
screened for FLT3 mutations and trial eligibility
254 Were excluded
247 Were assigned to receive
gilteritinib, 120 mg/day
124 Were assigned to receive
salvage chemotherapy
1 Did not receive trial therapy 15 Did not receive trial therapy
208 Discontinued trial




28 Had adverse event
11 Were withdrawn by
physician
5 Withdrew
4 Had other reason
109 Discontinued trial








5 Had adverse event
4 Had other reason
1 Had protocol deviation
63 Underwent hematopoietic stem-cell
transplantation
19 Underwent hematopoietic stem-cell
transplantation
38 Are continuing in the trial 0 Are continuing in the trial
246 Received gilteritinib and were 
included in safety population
109 Received salvage chemotherapy and 
were included in safety population
28 Received MEC
40 Received FLAG-IDA
16 Received  low-dose cytarabine
25 Received azacitidine
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refractory AML, the median overall survival was 
10.4 months in the gilteritinib group and 6.9 
months in the chemotherapy group (hazard ratio 
for death, 0.99; 95% CI, 0.63 to 1.55) (Table S3).
Although a higher percentage of patients un-
derwent transplantation in the gilteritinib group 
than in the chemotherapy group (25.5% [63 of 
247 patients] vs. 15.3% [19 of 124 patients]), the 
overall survival advantage for gilteritinib was 
also maintained when survival data were cen-
sored at the time of transplantation (hazard ratio 
for death, 0.58; 95% CI, 0.43 to 0.76) (Fig. S1). 
Survival outcomes in patients who had been 
preselected to receive high-intensity chemother-
apy or low-intensity chemotherapy and in those 
who had undergone transplantation previously 
are presented in Table S4.
The median event-free survival was 2.8 months 
in the gilteritinib group and 0.7 months in the 
chemotherapy group (hazard ratio for treatment 
failure or death, 0.79; 95% CI, 0.58 to 1.09) and 
did not differ significantly between the treatment 
groups (Fig. S2). Because the percentage of pa-









Median 62.0 62.0 61.5
Range 19.0–85.0 20.0–84.0 19.0–85.0
Female sex — no. (%) 201 (54.2) 131 (53.0) 70 (56.5)
Cytogenetic risk status — no. (%)
Favorable 5 (1.3) 4 (1.6) 1 (0.8)
Intermediate 271 (73.0) 182 (73.7) 89 (71.8)
Unfavorable 37 (10.0) 26 (10.5) 11 (8.9)
Unknown 58 (15.6) 35 (14.2) 23 (18.5)
Previous therapy for AML — no. (%)
Anthracycline 311 (83.8) 205 (83.0) 106 (85.5)
FLT3 inhibitor 46 (12.4) 32 (13.0) 14 (11.3)
HSCT 74 (19.9) 48 (19.4) 26 (21.0)
Response to first-line therapy before enroll-
ment — no. (%)†
Relapse 225 (60.6) 149 (60.3) 76 (61.3)
Primary refractory disease without HSCT 146 (39.4) 98 (39.7) 48 (38.7)
Preselected salvage chemotherapy per IRT — 
no. (%)
High-intensity chemotherapy 224 (60.4) 149 (60.3) 75 (60.5)
Low-intensity chemotherapy 147 (39.6) 98 (39.7) 49 (39.5)
FLT3 mutation subtype — no. (%)‡
ITD only 328 (88.4) 215 (87.0) 113 (91.1)
TKD only 31 (8.4) 21 (8.5) 10 (8.1)
ITD and TKD 7 (1.9) 7 (2.8) 0
*  The intention-to-treat population included all the patients who underwent randomization. Percentages may not total 
100 because of rounding. AML denotes acute myeloid leukemia, HSCT hematopoietic stem-cell transplantation, ITD 
 internal tandem duplication, and TKD tyrosine kinase domain.
†  Response was based on findings from interactive response technology (IRT).
‡  Central laboratory confirmed the FLT3 mutation status. Five patients (1.3%) had unconfirmed FLT3 mutations; four 
 patients (1.6%) were assigned to the gilteritinib group and one (0.8%) to the chemotherapy group.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline (Intention-to-Treat Population).*
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the low-intensity chemotherapy subgroup was 
4% (2 of 49 patients), the event-free survival in 
the chemotherapy group was largely derived 
from the high-intensity chemotherapy subgroup. 
Because relapse events were defined on the basis 
of central review of bone marrow biopsy speci-
mens, nearly all the patients who had a response 
to high-intensity chemotherapy and entered long-
term follow-up had their data censored for event-
free survival at 1 to 2 months after randomi-
zation, which limited the usefulness of the 
protocol-defined analysis of event-free survival. 
We performed a prespecified sensitivity analysis 
of event-free survival that included investigator-
reported events during the long-term follow-up 
period (including the initiation of new antileuke-
mic therapy), which showed event-free survival 
of 2.3 months in the gilteritinib group and 0.7 
months in the chemotherapy group (hazard ratio, 
0.50; 95% CI, 0.39 to 0.64) (Fig. S3).
The percentage of patients who had complete 
remission with full or partial hematologic recov-
ery was 34.0% in the gilteritinib group and 
15.3% in the chemotherapy group (risk difference, 
18.6 percentage points; 95% CI, 9.8 to 27.4); the 
percentages of patients with complete remission 
were 21.1% and 10.5%, respectively (risk differ-
ence, 10.6 percentage points; 95% CI, 2.8 to 18.4) 
(Table 2). The median duration of complete re-
mission with full or partial hematologic recov-
ery was 11.0 months in the gilteritinib group but 
could not be evaluated in the chemotherapy 
group because of censoring. The percentages of 
patients who had remission after an increase 
in the dose of gilteritinib (78 patients) or a de-
crease in the dose (58 patients) are shown in 
Table S5. When we excluded remissions that oc-
curred after transplantation during the trial, the 
percentage of patients who had complete remis-
sion with full or partial hematologic recovery 
was 26.3% in the gilteritinib group and 15.3% in 
the chemotherapy group (risk difference, 10.9 per-
centage points; 95% CI, 2.4 to 19.5). Among pa-
tients with primary refractory AML, the percent-
age of patients who had complete remission with 
full or partial hematologic recovery was 32% (31 
of 98 patients) in the gilteritinib group and 21% 
(10 of 48 patients) in the chemotherapy group 
(Table S3). The percentages of patients with a 
remission according to chemotherapy intensity 
and receipt or nonreceipt of previous transplan-
tation are presented in Table S4.
Among patients with FLT3 ITD mutations who 
had been randomly assigned to the gilteritinib 
group, 20.5% had a complete remission; among 
those who had been randomly assigned to chemo-
therapy, 9.7% had a complete remission (Table 
S6). Although the percentages of patients with 
complete remission were similar across the treat-
ment groups among patients with FLT3 TKD 
mutations, gilteritinib therapy resulted in similar 
percentages of complete remission among pa-
tients with FLT3 TKD mutations alone (19.0%) 
and among those with FLT3 ITD mutations alone 
(20.5%) (Table S6). Among patients treated with 
gilteritinib, the median overall survival was 
similar among those with FLT3 ITD mutations 
alone (9.3 months) and those with FLT3 TKD 
mutations alone (8.0 months). The most com-
monly co-mutated genes were NPM1 (46.6%) and 
DNMT3A (31.0%). Longer survival was observed 
with gilteritinib than with chemotherapy across 
all cohorts of patients with co-mutations, particu-
larly in the cohort of patients with double muta-
tion (DNMT3A and NPM1). Baseline levels of AXL 
expression did not influence survival with gilteri-
tinib. (Details are provided in Figs. S4 and S5.)
Overall, 197 of 247 patients (79.8%) who had 
been randomly assigned to the gilteritinib group 
Figure 2 (facing page). Overall Survival among Patients 
with FLT3-Mutated Relapsed or Refractory AML Treated 
with Gilteritinib or Salvage Chemotherapy (Intention-to-
Treat Population).
Panel A shows the Kaplan–Meier estimate of overall 
survival, and Panel B the hazard ratio for death in sub-
group analyses. Two-sided P values were determined 
by the log-rank test; the Kaplan–Meier method in com-
bination with the Greenwood formula was used to de-
termine overall survival and corresponding 95% con-
fidence intervals (CIs). Tick marks indicate censored 
data. The forest plot is shown on a log2 scale. Arrows 
indicate confidence intervals that extend beyond the 
scale of the graph. Race was reported by the patients 
and was categorized by the investigators on the basis 
of the listed categories. Eastern Cooperative Oncology 
Group (ECOG) performance-status scores range from 
0 to 5, with higher scores indicating worse functional 
status and a score of 5 indicating death. Patients from 
Israel or Turkey were included with those from Europe. 
FLT3 mutation subtypes were internal tandem duplica-
tion (ITD) and tyrosine kinase domain (TKD) and were 
assessed centrally; other subtype included unknown, 
missing, or negative. HSCT denotes hematopoietic stem-
cell transplantation, IRT interactive response technology, 
and NE not evaluated.
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were transfusion-dependent at randomization. A 
total of 68 of these 197 patients (34.5%) became 
transfusion-independent.
Safety
The median duration of exposure to gilteritinib 
and chemotherapy was 18 weeks (interquartile 
range, 9 to 34) and 4 weeks (interquartile range, 
4 to 4), respectively; treatment exposure was 
121.7 patient-years and 11.9 patient-years, respec-
tively. The incidence of all exposure-adjusted ad-
verse events, including those that were consid-
ered by the investigator to be drug-related, was 
higher in the chemotherapy group than in the 
gilteritinib group. Similar results were observed 
regarding adverse events that occurred during 
the first 30 days of treatment, except for eleva-
tions of the liver aminotransferase levels. (Details 
are provided in Tables S7 and S8.)
Common adverse events of grade 3 or higher 
in the gilteritinib group were febrile neutropenia 
(45.9%), anemia (40.7%), and thrombocytopenia 
(22.8%) (Table 3 and Table S9); these were also 
the most common adverse events of grade 3 or 
higher that were considered by the investigators 
to be related to gilteritinib therapy (Table S10). 
The incidence of exposure-adjusted adverse events 
of grade 3 or higher was 19.34 events per pa-
tient-year in the gilteritinib group and 42.44 
events per patient-year in the chemotherapy 
group. Adverse events of grade 3 or higher that 
occurred during the first 30 days of treatment 
are presented in Table S8.






Hazard Ratio or 
Risk Difference (95% CI)†
Median overall survival (95% CI) — mo 9.3 (7.7–10.7) 5.6 (4.7–7.3) 0.64 (0.49–0.83)
Median event-free survival (95% CI) — mo 2.8 (1.4–3.7) 0.7 (0.2–NE) 0.79 (0.58–1.09)
Response — no. (%)
Complete remission 52 (21.1) 13 (10.5) 10.6 (2.8–18.4)
Complete remission or complete remission  
with partial hematologic recovery
84 (34.0) 19 (15.3) 18.6 (9.8–27.4)
Complete remission with partial hematologic  
recovery
32 (13.0) 6 (4.8) ND
Complete remission with incomplete hematologic 
recovery
63 (25.5) 14 (11.3) ND
Complete remission with incomplete platelet  
recovery
19 (7.7) 0 ND
Partial remission 33 (13.4) 5 (4.0) ND
No response 66 (26.7) 43 (34.7) ND
Composite complete remission‡ 134 (54.3) 27 (21.8) 32.5 (22.3–42.6)
Overall response 167 (67.6) 32 (25.8)
Median duration of remission (95% CI) — mo§ 11.0 (4.6–NE) NE (NE–NE) NE
Time to composite complete remission — mo 2.3±1.9 1.3±0.5 NA
Median leukemia-free survival (95% CI) — mo 4.4 (3.6–5.2) 6.7 (2.1–8.5) NE
*  Plus–minus values are means ±SD. Data shown are the best response at any time postbaseline. Data include 366 patients with central labora-
tory–confirmed FLT3 mutations and 5 patients with FLT3 mutations that were not confirmed by a central laboratory and were based on local 
laboratory testing. Response could not be evaluated (NE) in 14 patients (5.7%) in the gilteritinib group and in 49 (39.5%) in the salvage 
chemotherapy group. NA denotes not applicable, and ND not determined.
†  Hazard ratios are shown for survival analyses, and risk differences (shown in percentage points) are shown for between-group differences in 
the percentages of patients. In the analysis of overall survival, the hazard ratio is for death. In the analysis of event-free survival, the hazard 
ratio is for treatment failure (i.e., relapse or lack of remission) or death.
‡  Composite complete remission was defined as the combination of complete remission, complete remission with incomplete hematologic 
recovery, and complete remission with incomplete platelet recovery.
§  Duration of remission was defined as the duration of complete remission with full or partial hematologic recovery.
Table 2. Antileukemic Responses (Intention-to-Treat Population).*
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adverse events, including those that were consid-
ered by the investigator to be drug-related, was 
7.11 events per patient-year in the gilteritinib 
group and 9.24 events per patient-year in the 
chemotherapy group. The most common serious 
adverse events that were considered to be related 
to gilteritinib therapy were febrile neutropenia 
(23 patients [9.3%]), increase in the alanine amino-
transferase level (11 patients [4.5%]), and increase 
in the aspartate aminotransferase level (10 pa-
tients [4.1%]). Drug-related adverse events lead-
ing to the discontinuation of gilteritinib occurred 
in 27 patients (11.0%); the most common events 
were elevated aspartate aminotransferase level 
(4 patients [1.6%]), elevated alanine aminotrans-
ferase level (3 [1.2%]), and pneumonia (3 [1.2%]) 
(Table S11). Prolonged corrected QT intervals 
calculated with Fridericia’s formula (QTcF inter-
vals) that were considered to be possibly related 
to gilteritinib therapy occurred in 12 patients 
(4.9%), but only 1 patient (0.4%) had a maximum 
postbaseline increase in the mean QTcF interval 
of more than 500 msec. Dose reductions occurred 
in 6 patients who had a mean change from the 
baseline QTcF interval of more than 60 msec.
There were 251 deaths in the safety popula-
tion of 355 patients, including 170 deaths among 
246 patients (69.1%) in the gilteritinib group and 
81 deaths among 109 patients (74.3%) in the 
chemotherapy group. In the intention-to-treat 
population, mortality at 30 days and at 60 days 
was 2.0% and 7.7%, respectively, in the gilteri-
tinib group and 10.2% and 19.0%, respectively, 
in the chemotherapy group. Common fatal ad-













number of patients (percent)
Febrile neutropenia 115 (46.7) 113 (45.9) 76 (30.9) 40 (36.7) 40 (36.7) 9 (8.3)
Anemia 116 (47.2) 100 (40.7) 8 (3.3) 38 (34.9) 33 (30.3) 0
Pyrexia 105 (42.7) 8 (3.3) 32 (13.0) 32 (29.4) 4 (3.7) 1 (0.9)
Alanine aminotransferase  
increased
103 (41.9) 34 (13.8) 13 (5.3) 10 (9.2) 5 (4.6) 0
Diarrhea 81 (32.9) 9 (3.7) 10 (4.1) 32 (29.4) 3 (2.8) 0
Aspartate aminotransferase  
increased
99 (40.2) 36 (14.6) 10 (4.1) 13 (11.9) 2 (1.8) 0
Hypokalemia 71 (28.9) 32 (13.0) 0 34 (31.2) 12 (11.0) 1 (0.9)
Constipation 76 (30.9) 2 (0.8) 0 16 (14.7) 0 0
Fatigue 70 (28.5) 6 (2.4) 4 (1.6) 14 (12.8) 2 (1.8) 1 (0.9)
Platelet count decreased 56 (22.8) 54 (22.0) 5 (2.0) 28 (25.7) 27 (24.8) 0
Cough 72 (29.3) 1 (0.4) 2 (0.8) 11 (10.1) 0 0
Thrombocytopenia 63 (25.6) 56 (22.8) 4 (1.6) 18 (16.5) 18 (16.5) 1 (0.9)
Headache 64 (26.0) 3 (1.2) 5 (2.0) 16 (14.7) 0 0
Peripheral edema 59 (24.0) 1 (0.4) 0 13 (11.9) 0 0
Vomiting 53 (21.5) 1 (0.4) 1 (0.4) 15 (13.8) 0 0
Dyspnea 58 (23.6) 10 (4.1) 10 (4.1) 7 (6.4) 3 (2.8) 2 (1.8)
Blood alkaline phosphatase  
increased
56 (22.8) 7 (2.8) 1 (0.4) 2 (1.8) 0 0
*  The events shown are limited to adverse events that had a difference in incidence of more than 2 percentage points between the treatment 
groups. The safety population comprised all the patients who had received at least one dose of trial treatment.
Table 3. Incidence of Adverse Events during Treatment That Occurred in at Least 20% of the Patients in Either Treatment Group (Safety 
Analysis Population).*
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verse events in both groups were disease pro-
gression (30 patients [12.2%] in the gilteritinib 
group and 5 patients [4.6%] in the chemother-
apy group) and infection (28 patients [11.4%] and 
7 patients [6.4%], respectively). The most com-
mon fatal adverse events that were considered by 
the investigator to be drug-related in the gilteri-
tinib group were pneumonia (3 patients [1.2%]), 
large intestine perforation (2 [0.8%]), and septic 
shock (2 [0.8%]); those in the chemotherapy 
group were sepsis (2 patients [1.8%]) and respi-
ratory failure (2 [1.8%]) (Table S12).
Discussion
Treatment options for patients with relapsed or 
refractory FLT3-mutated AML are largely limited 
to various salvage chemotherapy regimens, and 
there is no consensus regarding an approach. 
We found that in this population of patients, 
gilteritinib resulted in superior overall survival 
and percentages of remission as compared with 
salvage chemotherapy.
The efficacy of midostaurin plus chemother-
apy for newly diagnosed FLT3-mutated AML 
showed the usefulness of targeting FLT319; how-
ever, midostaurin has negligible activity in pa-
tients with relapsed or refractory AML.14 Results 
from a similarly designed trial (QuANTUM-R) 
that compared quizartinib with salvage chemo-
therapy in patients with FLT3 ITD–positive re-
lapsed or refractory AML provide further evi-
dence that targeting FLT3 prolongs survival as 
compared with salvage chemotherapy.21 The pres-
ent trial enrolled patients with FLT3 ITD or FLT3 
TKD mutations. Although FLT3 TKD mutations 
are uncommon at disease recurrence, they con-
sistently and rapidly emerge during FLT3 inhibi-
tor therapy to confer secondary resistance.22,34 
Gilteritinib had clinical activity in all studied 
FLT3 mutation types. Not only were the percent-
ages of patients with complete remission similar 
in the FLT3 TKD and ITD cohorts, but the me-
dian overall survival in these two cohorts was 
also similar. Small sample sizes and challenges 
of multiple comparisons limit the statistical 
power and conclusiveness of subgroup analyses, 
including the subgroup analyses of FLT3 TKD–
positive relapsed or refractory AML (38 patients) 
and primary refractory AML (146 patients). Over-
all, gilteritinib showed a consistent survival bene-
fit across many subgroups.
Our trial showed a survival advantage for 
FLT3-targeted therapy in patients with relapsed 
or refractory AML after data were censored for 
transplantation. Although gilteritinib therapy 
resulted in 63 patients being able to undergo 
transplantation, the contribution of the trans-
plantation to the survival benefit from gilteritinib 
is difficult to assess. Although long-term survival 
after transplantation appeared to be associated 
with resumption of gilteritinib therapy, many fac-
tors may have contributed to this observation; we 
therefore caution against overinterpretation of 
this nonrandomized analysis. Regardless of trans-
plantation, few patients with long-term survival 
were observed in either treatment group. Trials of 
gilteritinib as part of first-line induction or con-
solidation therapy and as postconsolidation or post-
transplantation maintenance therapy (ClinicalTrials 
.gov numbers, NCT02927262, NCT02997202, and 
NCT02752035) are under way to assess the role 
of timing of anti-FLT3 intervention in improving 
treatment outcomes.
A limitation is that our trial design provided 
an imperfect estimate of response duration in 
the chemotherapy group for the comparison of 
event-free survival. In addition, enrollment oc-
curred before widespread use of midostaurin in 
first-line chemotherapy, which could plausibly 
generate resistance to FLT3-targeted therapy and 
subsequently alter gilteritinib activity. Evidence 
suggests that mutational activation of RAS–RAF 
and related mitogen-associated protein kinase 
signaling frequently underlies secondary clinical 
resistance to gilteritinib,35 but the causes of pri-
mary resistance require further investigation.
In conclusion, gilteritinib therapy led to higher 
percentages of patients with response and longer 
survival than salvage chemotherapy among pa-
tients with relapsed or refractory FLT3-mutated 
AML. The main toxic effect was myelosuppres-
sion. A small signal regarding hepatic toxic ef-
fects bears attention in future studies.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
Supported by Astellas Pharma.
Dr. Perl reports receiving grant support, paid to his institu-
tion, consulting fees, and travel support from Astellas Pharma 
and Daiichi Sankyo, consulting fees and travel support from 
Arog Pharmaceuticals, grant support, paid to his institution, 
fees for serving on an advisory board, and travel support from 
Novartis, fees for serving on an advisory board from Pfizer, 
grant support, paid to his institution, and fees for serving on an 
advisory board from Actinium Pharmaceuticals, fees for serving 
on an advisory board and travel support from Jazz Pharmaceuti-
cals, Takeda Oncology, NewLink Genetics, Asana BioSciences, 
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on November 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;18 nejm.org October 31, 2019 1739
Gilteritinib for Relapsed or Refr actory FLT3-Mutated AML
Seattle Genetics, and Agios, grant support, paid to his institu-
tion, fees for serving on an advisory board, consulting fees, and 
travel support from AbbVie, and grant support, paid to his insti-
tution, from Bayer, Fujifilm, and BioMed Valley Discoveries; Dr. 
Martinelli, receiving grant support and consulting fees from 
Amgen, Ariad Pharmaceuticals, Incyte, Pfizer, Roche, Celgene, 
Janssen, AbbVie, and Novartis; Dr. Cortes, receiving grant sup-
port and consulting fees from Daiichi Sankyo and Novartis and 
grant support from Arog Pharmaceuticals; Dr. Berman, receiv-
ing fees for serving on an advisory board from Astellas Pharma; 
Dr. Montesinos, receiving fees for serving on an advisory board 
from AbbVie and Jazz Pharmaceuticals, grant support, consult-
ing fees, fees for serving on a speakers’ bureau, and fees for 
serving on an advisory board from Celgene and Daiichi Sankyo, 
fees for serving on a speakers’ bureau and fees for serving on an 
advisory board from Incyte, grant support, fees for serving on a 
speakers’ bureau, and fees for serving on an advisory board 
from Janssen, Novartis, Pfizer, and Teva Pharmaceutical Indus-
tries, and grant support and fees for serving on an advisory 
board from Karyopharm; Dr. Baer, receiving grant support from 
AbbVie, AI Therapeutics, Forma Therapeutics, Incyte, Kite 
Pharma, and Takeda Oncology; Dr. Larson, receiving grant sup-
port and consulting fees from Novartis and Daiichi Sankyo; Dr. 
Ustun, receiving fees for serving on a speakers’ bureau from 
Novartis; Dr. Erba, receiving grant support, fees for serving on a 
speakers’ bureau, and consulting fees from Agios, receiving 
grant support and consulting fees from Amgen, Astellas Pharma, 
Daiichi Sankyo, ImmunoGen, MacroGenics, Pfizer, and Seattle 
Genetics, receiving fees for serving on a speakers’ bureau and 
consulting fees from and serving as chair of a steering commit-
tee for Celgene, receiving grant support and consulting fees 
from and serving as a data and safety monitoring committee 
chair for Glycomimetics, receiving fees for serving on a speakers’ 
bureau and consulting fees from Incyte, Jazz Pharmaceuticals, 
and Novartis, receiving grant support from Janssen, Juno Thera-
peutics, and Takeda Oncology–Millennium Pharmaceuticals, 
receiving consulting fees from Ono Pharmaceutical, and serving 
as chair of an independent review committee for Covance; Dr. 
Olin, receiving honoraria from Jazz Pharmaceuticals, fees for 
serving as site primary investigator from Daiichi Sankyo and 
Pfizer, and fees for serving on an advisory board and for serving 
as site primary investigator from Genentech; Dr. Kasner, receiv-
ing grant support from Astellas Pharma, Pfizer, Daiichi Sankyo, 
Ono Pharmaceutical, and Roche, grant support and fees for 
serving on an advisory board from Otsuka Pharmaceutical, and 
fees for serving on an advisory board from Jazz Pharmaceuti-
cals; Dr. Podoltsev, receiving fees for serving on an advisory 
board from Alexion, Pfizer, CTI BioPharma, Agios, Blueprint 
Medicines, Incyte, and Novartis, grant support, paid to his insti-
tution, from Boehringer Ingelheim, Daiichi Sankyo, Sunesis 
Pharmaceuticals, Celator Pharmaceuticals, Pfizer, Astex Pharma-
ceuticals, CTI BioPharma, Genentech, AI Therapeutics, Samus 
Therapeutics, Arog Pharmaceuticals, and Kartos Therapeutics, 
and grant support from Celgene; Dr. Recher, receiving grant 
support and honoraria from Celgene, Sunesis Pharmaceuticals, 
Amgen, Novartis, Jazz Pharmaceuticals, Astellas Pharma, and 
Daiichi Sankyo and honoraria from Incyte, AbbVie, MacroGenics, 
and Otsuka Pharmaceutical; Dr. Yokoyama, receiving travel sup-
port from Astellas Pharma; Dr. Pardee, receiving fees for serving 
on a speakers’ bureau from Celgene, Amgen, and Pharmacyclics 
and grant support from Karyopharm and being employed by 
Rafael Pharmaceuticals; Dr. Fathi, receiving grant support, con-
sulting fees, and fees for serving on an advisory board from 
Celgene, Seattle Genetics, and Takeda Oncology, fees for serv-
ing on an advisory board from Jazz Pharmaceuticals, PTC Thera-
peutics, and NewLink Genetics, consulting fees from MedIm-
mune, Clear Creek Bio, and Novartis, grant support from 
Exelexis, grant support and fees for serving on an advisory 
board from Agios, and fees for serving on an advisory board and 
consulting fees from Boston Biomedical and Daiichi Sankyo; 
Drs. C. Liu, Hasabou, X. Liu, and Bahceci, being employed by 
Astellas Pharma; and Dr. Levis, receiving grant support from 
Novartis and Fujifilm, honoraria from Daiichi Sankyo, and fees 
for serving on an advisory board from Menarini Group, Agios, 
and Amgen. No other potential conflict of interest relevant to 
this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank all the patients and their families for participating 
in this trial; the trial site coordinators and personnel; Kalpana 
Vijayan, Ph.D., Stephan Lindsey, Ph.D., and Elizabeth Hermans, 
Ph.D., of OPEN Health Medical Communications, for assistance 
with an earlier version of the manuscript; and Qiaoyang Lu, 
M.S., of Astellas Pharma, for statistical analyses.
Appendix
The authors’ full names and academic degrees are as follows: Alexander E. Perl, M.D., Giovanni Martinelli, M.D., Jorge E. Cortes, M.D., 
Andreas Neubauer, M.D., Ellin Berman, M.D., Stefania Paolini, M.D., Ph.D., Pau Montesinos, M.D., Maria R. Baer, M.D., Richard A. 
Larson, M.D., Celalettin Ustun, M.D., Francesco Fabbiano, M.D., Harry P. Erba, M.D., Ph.D., Antonio Di Stasi, M.D., Robert Stuart, 
M.D., Rebecca Olin, M.D., Margaret Kasner, M.D., Fabio Ciceri, M.D., Wen-Chien Chou, M.D., Ph.D., Nikolai Podoltsev, M.D., Chris-
tian Recher, M.D., Hisayuki Yokoyama, M.D., Naoko Hosono, M.D., Ph.D., Sung-Soo Yoon, M.D., Ph.D., Je-Hwan Lee, M.D., Ph.D., 
Timothy Pardee, M.D., Ph.D., Amir T. Fathi, M.D., Chaofeng Liu, Ph.D., Nahla Hasabou, M.D., Xuan Liu, Ph.D., Erkut Bahceci, M.D., 
and Mark J. Levis, M.D., Ph.D.
The authors’ affiliations are as follows: the Abramson Cancer Center, University of Pennsylvania (A.E.P.), and Thomas Jefferson 
University (M.K.) — both in Philadelphia; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto Di Ricovero e Cura 
a Carattere Scientifico (IRCCS), Meldola (G.M.), L. and A. Seràgnoli Institute of Hematology, Bologna University Medical School, Bolo-
gna (S.P.), Ospedali Riuniti Villa Sofia-Cervello, Palermo (F.F.), and IRCCS San Raffaele Scientific Institute, Milan (F.C.) — all in Italy; 
University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Universitätsklinikum Giessen und Marburg, Marburg, Germany 
(A.N.); Memorial Sloan Kettering Cancer Center, New York (E. Berman); Hospital Universitari i Politècnic La Fe, Valencia, and Centro 
de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto Carlos III, Madrid — both in Spain (P.M.); University of Maryland 
Greenebaum Comprehensive Cancer Center (M.R.B.) and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University 
(M.J.L.) — both in Baltimore; University of Chicago, Chicago (R.A.L.), and Astellas Pharma, Northbrook (C.L., N. Hasabou, X.L., E. 
Bahceci) — both in Illinois; University of Minnesota, Minneapolis (C.U.); University of Alabama at Birmingham, Birmingham (H.P.E., 
A.D.S.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.S.); University of California, San Francisco, San 
Francisco (R.O.); National Taiwan University, Taipei City, Taiwan (W.-C.C.); Yale University School of Medicine, New Haven, CT (N.P.); 
Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Saba-
tier, Toulouse, France (C.R.); Sendai Medical Center, National Hospital Organization, Sendai (H.Y.), and University of Fukui, Fukui (N. 
Hosono) — both in Japan; Seoul National University (S.-S.Y.) and Asan Medical Center, University of Ulsan College of Medicine (J.-H.L.) 
— both in Seoul, South Korea; Wake Forest Baptist Medical Center, Winston-Salem, NC (T.P.); and Massachusetts General Hospital, 
Harvard Medical School, Boston (A.T.F.).
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on November 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;18 nejm.org October 31, 20191740
Gilteritinib for Relapsed or Refr actory FLT3-Mutated AML
References
1. Litzow MR, Othus M, Cripe LD, et al. 
Failure of three novel regimens to im-
prove outcome for patients with relapsed 
or refractory acute myeloid leukaemia: 
a report from the Eastern Cooperative On-
cology Group. Br J Haematol 2010; 148: 
217-25.
2. Roboz GJ, Rosenblat T, Arellano M, 
et al. International randomized phase III 
study of elacytarabine versus investigator 
choice in patients with relapsed/refractory 
acute myeloid leukemia. J Clin Oncol 2014; 
32: 1919-26.
3. Ravandi F, Ritchie EK, Sayar H, et al. 
Vosaroxin plus cytarabine versus placebo 
plus cytarabine in patients with first re-
lapsed or refractory acute myeloid leukae-
mia (VALOR): a randomised, controlled, 
double-blind, multinational, phase 3 study. 
Lancet Oncol 2015; 16: 1025-36.
4. Megías-Vericat JE, Martínez-Cuadrón 
D, Sanz MA, Montesinos P. Salvage regi-
mens using conventional chemotherapy 
agents for relapsed/refractory adult AML 
patients: a systematic literature review. 
Ann Hematol 2018; 97: 1115-53.
5. Small D, Levenstein M, Kim E, et al. 
STK-1, the human homolog of Flk-2/Flt-3, 
is selectively expressed in CD34+ human 
bone marrow cells and is involved in the 
proliferation of early progenitor/stem cells. 
Proc Natl Acad Sci U S A 1994; 91: 459-63.
6. Ravandi F, Kantarjian H, Faderl S, et al. 
Outcome of patients with FLT3-mutated 
acute myeloid leukemia in first relapse. 
Leuk Res 2010; 34: 752-6.
7. Nakao M, Yokota S, Iwai T, et al. Inter-
nal tandem duplication of the flt3 gene 
found in acute myeloid leukemia. Leuke-
mia 1996; 10: 1911-8.
8. Kiyoi H, Towatari M, Yokota S, et al. 
Internal tandem duplication of the FLT3 
gene is a novel modality of elongation 
mutation which causes constitutive acti-
vation of the product. Leukemia 1998; 12: 
1333-7.
9. Yamamoto Y, Kiyoi H, Nakano Y, et al. 
Activating mutation of D835 within the 
activation loop of FLT3 in human hemato-
logic malignancies. Blood 2001; 97: 2434-9.
10. Chevallier P, Labopin M, Turlure P, 
et al. A new Leukemia Prognostic Scor-
ing System for refractory/relapsed adult 
acute myelogeneous leukaemia patients: 
a GOELAMS study. Leukemia 2011; 25: 
939-44.
11. Papaemmanuil E, Gerstung M, Bull-
inger L, et al. Genomic classification and 
prognosis in acute myeloid leukemia. 
N Engl J Med 2016; 374: 2209-21.
12. Wattad M, Weber D, Döhner K, et al. 
Impact of salvage regimens on response 
and overall survival in acute myeloid leu-
kemia with induction failure. Leukemia 
2017; 31: 1306-13.
13. Smith BD, Levis M, Beran M, et al. 
Single-agent CEP-701, a novel FLT3 in-
hibitor, shows biologic and clinical activ-
ity in patients with relapsed or refractory 
acute myeloid leukemia. Blood 2004; 103: 
3669-76.
14. Fischer T, Stone RM, Deangelo DJ, 
et al. Phase IIB trial of oral midostaurin 
(PKC412), the FMS-like tyrosine kinase 3 
receptor (FLT3) and multi-targeted kinase 
inhibitor, in patients with acute myeloid 
leukemia and high-risk myelodysplastic 
syndrome with either wild-type or mutat-
ed FLT3. J Clin Oncol 2010; 28: 4339-45.
15. Cortes J, Perl AE, Döhner H, et al. 
Quizartinib, an FLT3 inhibitor, as mono-
therapy in patients with relapsed or refrac-
tory acute myeloid leukaemia: an open-
label, multicentre, single-arm, phase 2 
trial. Lancet Oncol 2018; 19: 889-903.
16. Borthakur G, Kantarjian H, Ravandi 
F, et al. Phase I study of sorafenib in pa-
tients with refractory or relapsed acute 
leukemias. Haematologica 2011; 96: 62-8.
17. Galanis A, Ma H, Rajkhowa T, et al. 
Crenolanib is a potent inhibitor of FLT3 
with activity against resistance-conferring 
point mutants. Blood 2014; 123: 94-100.
18. RYDAPT (midostaurin) prescribing in-
formation. East Hanover, NJ: Novartis 
(https://www .pharma .us .novartis .com/ sites/ 
www .pharma .us .novartis .com/ files/ rydapt 
.pdf).
19. Stone RM, Mandrekar SJ, Sanford BL, 
et al. Midostaurin plus chemotherapy for 
acute myeloid leukemia with a FLT3 muta-
tion. N Engl J Med 2017; 377: 454-64.
20. Levis M, Ravandi F, Wang ES, et al. 
Results from a randomized trial of sal-
vage chemotherapy followed by lestaur-
tinib for patients with FLT3 mutant AML 
in first relapse. Blood 2011; 117: 3294-301.
21. Cortes JE, Khaled SK, Martinelli G, 
et al. Quizartinib versus salvage chemo-
therapy in relapsed or refractory FLT3-ITD 
acute myeloid leukaemia (QuANTUM-R): 
a multicentre, randomised, controlled, 
open-label, phase 3 trial. Lancet Oncol 
2019; 20: 984-97.
22. Smith CC, Wang Q, Chin CS, et al. 
Validation of ITD mutations in FLT3 as a 
therapeutic target in human acute my-
eloid leukaemia. Nature 2012; 485: 260-3.
23. Man CH, Fung TK, Ho C, et al. 
Sorafenib treatment of FLT3-ITD(+) acute 
myeloid leukemia: favorable initial out-
come and mechanisms of subsequent non-
responsiveness associated with the emer-
gence of a D835 mutation. Blood 2012; 
119: 5133-43.
24. Galanis A, Levis M. Inhibition of c-Kit 
by tyrosine kinase inhibitors. Haemato-
logica 2015; 100(3): e77-e79.
25. Lee LY, Hernandez D, Rajkhowa T, 
et al. Preclinical studies of gilteritinib, a 
next-generation FLT3 inhibitor. Blood 2017; 
129: 257-60.
26. Mori M, Kaneko N, Ueno Y, et al. Gil-
teritinib, a FLT3/AXL inhibitor, shows anti-
leukemic activity in mouse models of FLT3 
mutated acute myeloid leukemia. Invest 
New Drugs 2017; 35: 556-65.
27. Park IK, Mishra A, Chandler J, Whit-
man SP, Marcucci G, Caligiuri MA. Inhi-
bition of the receptor tyrosine kinase Axl 
impedes activation of the FLT3 internal 
tandem duplication in human acute my-
eloid leukemia: implications for Axl as a 
potential therapeutic target. Blood 2013; 
121: 2064-73.
28. Perl AE, Altman JK, Cortes J, et al. 
Selective inhibition of FLT3 by gilteritinib 
in relapsed or refractory acute myeloid 
leukaemia: a multicentre, first-in-human, 
open-label, phase 1-2 study. Lancet Oncol 
2017; 18: 1061-75.
29. Murphy KM, Levis M, Hafez MJ, et al. 
Detection of FLT3 internal tandem dupli-
cation and D835 mutations by a multiplex 
polymerase chain reaction and capillary 
electrophoresis assay. J Mol Diagn 2003; 5: 
96-102.
30. Jackson G, Taylor P, Smith GM, et al. 
A multicentre, open, non-comparative 
phase II study of a combination of fluda-
rabine phosphate, cytarabine and granulo-
cyte colony-stimulating factor in relapsed 
and refractory acute myeloid leukaemia 
and de novo refractory anaemia with ex-
cess of blasts in transformation. Br J Hae-
matol 2001; 112: 127-37.
31. Cheson BD, Bennett JM, Kopecky KJ, 
et al. Revised recommendations of the In-
ternational Working Group for Diagnosis, 
Standardization of Response Criteria, 
Treatment Outcomes, and Reporting Stan-
dards for Therapeutic Trials in Acute My-
eloid Leukemia. J Clin Oncol 2003; 21: 
4642-9.
32. Herdman M, Gudex C, Lloyd A, et al. 
Development and preliminary testing 
of the new five-level version of EQ-5D 
(EQ-5D-5L). Qual Life Res 2011; 20: 1727-36.
33. Cella D, Jensen SE, Webster K, et al. 
Measuring health-related quality of life in 
leukemia: the Functional Assessment of 
Cancer Therapy — Leukemia (FACT-Leu) 
questionnaire. Value Health 2012; 15: 
1051-8.
34. Smith CC, Lin K, Stecula A, Sali A, 
Shah NP. FLT3 D835 mutations confer 
differential resistance to type II FLT3 in-
hibitors. Leukemia 2015; 29: 2390-2.
35. McMahon CM, Ferng T, Canaani J, et 
al. Clonal selection with Ras pathway ac-
tivation mediates secondary clinical resis-
tance to selective FLT3 inhibition in acute 
myeloid leukemia. Cancer Discov 2019; 9: 
1050-63.
Copyright © 2019 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on November 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
